PharmaCyte Biotech, Inc.

3960 Howard Hughes Parkway, Suite 500

Las Vegas, NV 89169



September 27, 2023




U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Doris Stacey Gama and Joe McCann


Re: PharmaCyte Biotech, Inc.
  Registration Statement on Form S-3
  Filed September 12, 2023
  File No. 333-272569 (the “Registration Statement”)
  Acceleration Request


Ladies and Gentlemen:


In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, September 29, 2023, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable.


The cooperation of the staff in meeting the timetable described above is very much appreciated.


Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request.


  Very truly yours,
  /s/ Joshua N. Silverman
  Joshua N. Silverman
  Interim Chief Executive Officer and Interim President

cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Kenneth R. Koch, Esq.  
Daniel A. Bagliebter, Esq.